Thus, this study demonstrates that secretory PD-L1 inhibitors, GM-CSF, and viral oncolysis work synergistically to promote neoantigen presentation and activate tumor neoantigen-specific T cell response, representing a potent, individual tumor-specific oncolytic immunotherapy. The gene discussed is CSF2; the disease is neoplasm.